By Pete Brush ( February 29, 2012, 12:03 PM EST) -- Dainippon Sumitomo Pharma Co. Ltd. has struck a deal to buy Boston Biomedical Inc., a developer of promising cancer stem cell anti-tumor drugs, for $200 million up front plus milestone payments that could top $2.4 billion, for a total of $2.6 billion, the Japanese buyer said Wednesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.